NASDAQ · ELABHealthcarePharmaceuticals

PMGC Holdings financials

$3.67−23.22%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
Revenue$590.1K$0.00$0.00
Gross profit$185.3K$0.00$0.00
Gross margin31.4%——
Operating income-$6.9M-$3.7M-$1.1M
Net income-$7.7M-$6.2M-$4.3M
Net margin−1313.0%——
Diluted EPS$-3806.83$-65952.90$-470724.24
EBITDA-$6.8M-$3.6M-$1.1M
Operating cash flow-$5.9M-$5.5M-$4.6M
Free cash flow-$6.4M-$5.5M-$4.6M
Diluted shares0.0M0.0M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31
Cash & equivalents$5.4M$4.0M$3.3M
Short-term investments$572.1K$0.00$0.00
Total debt$1.4M$0.00$0.00
Total assets$12.9M$9.0M$5.2M
Total liabilities$5.0M$2.3M$1.4M
Shareholders' equity$7.8M$6.7M$3.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology